Rodney Hicks, MD University of Melbourne, Melbourne, Australia
- Status: Active
- Year(s): 2018
- Grant Type: Accelerator
- Research Type: Clinical
- Primary Tumor Site: Other
- Area of Inquiry: Clinical trials
General DescriptionThis four-year Accelerator Project will include both laboratory tests and clinical trials aimed at improving the clinical benefits of PRRT. While some patients respond well to PRRT, others are resistant to this type of therapy. By understanding what drives this resistance, investigators hope to improve durable response, and therefore widen the pool of patients who benefit from PRRT. Hicks and colleagues will evaluate the impact of PRRT on tumor cells’ ability to recognize and repair radiation damage. To prevent cancer cell repair, the investigators will combine PRRT with therapies that block DNA-repair mechanisms. Laboratory studies will identify which targeted therapies “turn off” cellular repair mechanisms. Then, a pilot clinical trial will test the targeted therapies in combination with PRRT in patients.
- State: International
- Grant Duration: 4 years
- Awards: Accelerator Grant
- Sponsor: Margie & Robert E. Petersen Foundation
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.